NeuroSearch provides an update on the development plan for Huntexil® in the treatment of Huntington's disease

NeuroSearch provides an update on the development plan for Huntexil® in the treatment of Huntington's disease following the End of Phase II meeting with the FDA

NeuroSearch has received preliminary feedback from the FDA regarding the development programme for Huntexil® in the treatment of Huntington's disease
Based on the preliminary feedback, new confirmatory clinical data to support an NDA submission in the US will be required
NeuroSearch will await confirmation from FDA as well as feedback from EMA, which is expected in Q2 2011, before defining the global development plan and regulatory strategies for Huntexil®

NeuroSearch (NEUR) has completed an End of Phase II meeting with the United States Food and Drug Administration (FDA). Based on the preliminary feedback from the FDA, a US regulatory submission will require additional clinical data to support the effect of Huntexil® in the treatment of Huntington's disease.

A plan for the generation of additional clinical evidence for Huntexil® in Huntington's disease is currently being developed. However, before defining the global development and regulatory strategies, NeuroSearch will await the final meeting minutes from the FDA and feedback from EMA, which is expected in the second quarter of 2011.

Patrik Dahlen
CEO

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.